Skip to main content

Nasdaq Set to Delist Genomic Solutions; Company to Appeal

NEW YORK, Sept. 18 - Genomic Solutions today said it will appeal a decision by the Nasdaq exchange to delist the company's stock.

 

The Nasdaq informed Genomic Solutions of its intent on Sept. 12 after the company failed over 90 calendar days to raise its share price above $1. The letter followed a warning the exchange sent the company in mid-June for failing to keep its share price above $1 for 30 consecutive trading days.

 

Genomics solutions, which received the delisting notification on Sept. 12 but disclosed the news after the markets closed today, said it has requested a hearing before the Nasdaq Listing Qualifications Panel. A date for the appeal has not yet been set.

 

Steven Richvalsky, Genomic Solutions' CFO, was unavailable for comment. A company statement stressed that an appeal does not guarantee it will continue listing on the exchange.

 

Shares in Genomic Solutions closed down $.24 to $.47 today.

 

The company is set to be acquired by Harvard Bioscience in the fourth quarter. It was not immediately clear whether a delisting would affect the planned acquisition.

The Scan

Response Too Slow, Cautious

A new report criticizes the global response to the threat of the COVID-19 pandemic, Nature News reports.

Pushed a Bit Later

Novavax has pushed back its timeline for filing for authorization for its SARS-CoV-2 vaccine, according to Bloomberg.

AMA Announces Anti-Racism Effort

The Associated Press reports that the American Medical Association has released a plan to address systemic racism in healthcare.

Nucleic Acids Research Papers on miRMaster 2.0, MutationTaster2021, LipidSuite

In Nucleic Acids Research this week: tool to examine small non-coding RNAs, approach to predict ramifications of DNA variants, and more.